MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Sunday, November 13, 2016

Remyelinating Monoclonal Antibody for Treatment of MS


Click here to receive MS news via e-mail

rHIgM22 is a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). A second Phase 1 trial in people with MS is currently recruiting patients experiencing an acute relapse. We expect to complete this trial in the first half of 2017.
In April 2015, Acorda presented data from its first Phase 1 clinical trial of rHIgM22. Safety data showed it was well-tolerated in each of the five tested doses, supporting additional clinical development. In addition, testing detected rHIgM22 in cerebrospinal fluid, indicating the drug’s access to the central nervous system. These data were presented at the 67th American Academy of Neurology Annual Meeting.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: